Why Late Afternoon Can Be the Hardest Time for Caregivers
The combination of circadian decline and caregiver fatigue makes late afternoon a predictable crisis point in dementia care.
Category Alzheimer’s
Leqembi delivers 83 percent stabilization rates for early-stage Alzheimer’s disease patients
A new Alzheimer's drug shows the ability to stabilize cognitive function in most early-stage patients—but access and side effects complicate the picture.
The Difference Between Forgetfulness, Alzheimer’s, and Dementia
Normal memory lapses differ from dementia in severity, progression, and impact on daily independence.
What Makes Alzheimer’s Different From Other Dementias
Alzheimer's and other dementias look different under the microscope, progress at different speeds, and respond to different treatments—understanding the distinctions matters.
Autopsy study reveals uneven effectiveness of Alzheimer’s medications across brain regions
Autopsy findings show why Alzheimer's drugs work in some brain regions but fail in others, reshaping expectations for treatment.
Alzheimer’s, Vascular Dementia, and Lewy Body Dementia Compared
Three distinct brain diseases cause dementia—Alzheimer's, vascular dementia, and Lewy body dementia—each with different causes, symptoms, and treatment approaches.
How Alzheimer’s Fits Into the Dementia Umbrella
Alzheimer's is one disease within the broader dementia category, accounting for most cases but not all, with distinct causes and progression patterns.
What Families Get Wrong About Alzheimer’s and Dementia
Most families misunderstand dementia's early signs, misconceive how medications work, and wait too long to plan.
Alzheimer’s vs Dementia: What Is the Difference
Dementia is a syndrome describing cognitive decline; Alzheimer's is the specific brain disease causing 60-80% of dementia cases.
Kisunla extended therapy option for continued Alzheimer’s disease management post-treatment phase
Extended Kisunla therapy offers sustained amyloid-targeting treatment post-initial phase, but requires ongoing monitoring and realistic expectations about disease-modifying benefit.